[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infection-bacterial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infection-bacterial":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,52,93,122,154,176,204,228,258,281,307],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100201862","clinical-microbial-species--antibiotic-resistance-id-in-ed-patients-presenting-with-infection---is-rapid-id-possible--accurate-100201862",false,"NCT01904188","Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?","Clinical Microbial Species and Antibiotic Resistance Identification in Patients Presenting to the Emergency Department With Three of Four Systemic Inflammatory Response Syndrome (SIRS) Criteria - is Rapid Identification Possible and Accurate?","Inclusion Criteria:\n\nAdult patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and\u002For urine collected for the evaluation of suspected sepsis, and\u002For other bodily fluids collected for culture and sensitivity analysis.\n\nPatients with other sources of infection with less than 3 of 4 SIRS criteria including sputum, wound drainage, CSF, nasal or oral secretions.\n\nExclusion Criteria:\n\nPediatric patients","ALL","18 Years",{"count":19,"type":20},2500,"ESTIMATED","OBSERVATIONAL","The aim of this project is to test the utility of The Gene Z device (as of 2018 Gene Z no longer being used), now using In-Dx and other rapid identification techniques that the investigators have developed in the lab on clinically obtained bodily fluid samples taken from patients with suspected infection or sepsis based on having three of four positive Systemic Inflammatory Response Syndrome markers, or having a known infection for which a specimen is being collected. Specimens will be collected at the University of Michigan Health\u002FSparrow and McLaren Greater Lansing , processed in our lab and stored for analysis at a later date to determine if the microbial pathogens identified by current methods of culture, as well as pathogen susceptibility to antibiotics by culture results, can be identified by the GeneZ technology (no longer in use) or other developed technology accurately, and more timely. It will not affect current patient care nor impact patient care, which will continue in the standard fashion today for sepsis. Results will be compared to standard culture results and antibiotic sensitivities. A secondary aim is related to the antibiotic resistance of the organism causing the infection in an attempt to determine if there are specific characteristics of the organism that allow it to be resistant to certain antibiotics. This requires analysis of the genetic material of the organism in our laboratory. Because there are also human cells in the specimens collected, with separate permission we will evaluate the human genome of the patient with the infection to determine characteristics and conditions that may predict a complicated versus uncomplicated disease course.",[24,25,26,27,28,29,30,31],"Sepsis","Systemic Inflammatory Response Syndrome","Infection Mixed","Infection, Bacterial","Infection, Fungal","Infection, Coronavirus","Antibiotic Resistance Genes","Human Genome Analysis",[33,34,35,36,25,37,38],"microbial identification","antibiotic resistance","In-Dx and other methods as developed","sepsis","antibiotic resistance genes","human genome analysis","RECRUITING","2026-06-04",{"date":42,"type":43},"2026-06-08","ACTUAL",{"date":45,"type":4},"2015-06",{"date":47,"type":20},"2032-07",{"name":49,"class":50},"Michigan State University","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100515587","optimising-kangaroo-care-to-reduce-neonatal-severe-infectionsepsis-and-resistant-bacterial-colonisation-among-high-risk-infants-in-nicu-100515587","NCT05993442","Optimising Kangaroo Care to Reduce Neonatal Severe Infection\u002FSepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.","Optimising Kangaroo Care to Reduce Neonatal Severe Infection\u002FSepsis and Resistant Bacterial Colonisation Among High-risk Infants in Neonatal Intensive Care: a Pragmatic, Multicentre, Parallel Cluster Randomised Hybrid Implementation-effectiveness Study.","NeoDeco","INCLUSION CRITERIA\n\n1\\. Site level\n\n1a. Neonatal unit that provide routinely cares for extremely premature infants (\\\u003C28 weeks' gestation).\n\n1b. Minimum capacity of 12 beds.\n\n1c. Access to a -70 to -80°C freezer for storage of research samples\n\n1d. Willing to implement optimised KC if allocated to the intervention group.\n\n1e. Willing to commit to offering the minimum expected target duration or an increase of 50% if neonatal unit is already offering \\>67% of the minimum expected target duration, if allocated to the intervention arm.\n\n1f. Prepared to implement NeoIPC surveillance.\n\n1. g. Adequate resources and expertise and approvals from relevant Research Ethics Committees, as appropriate.\n2. Infant level\n\n2a. All high-risk infants (born at \\\u003C32 weeks' gestation) admitted to participating neonatal units, regardless of complexity of care, anticipated hospitalisation duration, room type, or whether admitted directly after birth.\n\nEXCLUSION CRITERIA 1 Site level\n\n1. a. Participation in other research that could directly influence the study intervention or outcomes.\n2. a. Average StSC duration already exceeding 18 hours per day.\n3. a. Anticipated major changes in resistant bacterial colonisation pressure during the study\n\n2 Infant level 2a. No infant-level exclusion criteria for data collection. We exclude infants from individual data and sample collection if their parents or legal guardians do not provide written informed consent. These infants contribute to cluster-aggregated outcomes.","32 Weeks",{"count":62,"type":20},3080,"INTERVENTIONAL",[65],"NA","NeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial includes a baseline period, a wash-in phase, and a staggered randomisation approach. The primary focus of the NeoDeco study is on high-risk preterm infants born at less than 32 weeks' gestational age, a population particularly vulnerable to hospital-acquired infections and sepsis during their initial hospital stay. By investigating hospital-acquired infections specifically, the study targets the period during which optimised KC practices are likely to have the most significant impact.",[27,68],"Infection Prevention",[70,71,72,73,74,75,76,77,78,79,80,81],"Nosocomial Infection","Prevention","Cluster","Implementation science","Surveillance","Kangaroo Care","Skin to Skin Contact","Neonatal Intensive Care Unit","NICU","Neonatal severe infection","Resistant bacterial","Pre-term infants","2026-03-20",{"date":84,"type":43},"2026-03-25",{"date":86,"type":43},"2024-05-28",{"date":88,"type":20},"2026-05",{"name":90,"class":91},"PENTA Foundation","NETWORK",24,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":63,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100504291","phase-4-cat-bite-antibiotic-prophylaxis-for-the-handforearm-catbite-100504291","NCT05846399","CAT BITE Antibiotic Prophylaxis for the Hand\u002FForearm (CATBITE)","CAT BITE Antibiotic Prophylaxis and Durations for the Hand\u002FForearm (CATBITE): A Prospective, Randomized, Placebo-controlled, Double-blinded, Clinical Trial","CATBITE","Inclusion Criteria:\n\n* Patients greater or equal to 18 years of age.\n* Bitten by a cat.\n* Location of bite is the hand and\u002For forearm (distal to elbow).\n* Presenting \\\u003C24 hours following a cat bite to the hand\u002Fforearm.\n* English speaking\n\nExclusion Criteria:\n\n* Patients who present with active local or systemic infections\n\n  1. Purulent drainage from the cat bite\n  2. Redness AND swelling at the location of the cat bite\n* Having a fever \\>100.4° F or \\>38° C)-Received antibiotics within the past 30 days\n* Received antibiotics within the past 30 days\n* Patients unwilling to take study medication\n* Patients unwilling to attend scheduled follow-up evaluations or complete study forms\n* Pregnant Women\n* Type I hypersensitivity reaction to any of the study interventions\n* Immunocompromised patients (primary and secondary immunodeficiencies) Primary\n* Autoimmune Lymphoproliferative Syndrome (ALPS)\n* Autoimmune Polyglandular Syndrome type 1 (APS-1)\n* B-cell Expansion with Nuclear factor kappa-light-chain-enhancer of activated B cells and T-cell Anergy (BENTA) Disease\n* Caspase Eight Deficiency State (CEDS)\n* Caspase Recruitment Domain Family Member 9 (CARD9) Deficiency and Other Syndromes of Susceptibility to Candidiasis\n* Cartilage-hair hypoplasia\n* Chédiak-Higashi syndrome\n* Chronic Granulomatous Disease (CGD)\n* Common Variable Immunodeficiency (CVID)\n* Complement Deficiencies\n* Congenital Neutropenia Syndromes\n* Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) Deficiency\n* Cyclic neutropenia\n* DiGeorge syndrome\n* Dedicator Of Cytokinesis 8 (DOCK8) Deficiency\n* GATA-binding protein 2 (GATA2) Deficiency\n* Glycosylation Disorders with Immunodeficiency\n* Hyper-Immunoglobulin E Syndromes (HIES)\n* Hyper-Immunoglobulin M Syndromes\n* Interferon Gamma, Interleukin 12 and Interleukin 23 Deficiencies\n* Leukocyte Adhesion Deficiency (LAD) Types 1 and 2\n* Lipopolysaccharide Responsive Beige-Like Anchor Protein (LRBA) Deficiency\n* Phosphatidylinositol 3-kinase (PI3-Kinase) Disease\n* Phospholipase C gamma 2 (PLCG2) associated Antibody Deficiency and Immune Dysregulation (PLAID)\n* Severe Combined Immunodeficiency (SCID)\n* Selective Immunoglobulin A (IgA) deficiency\n* Signal transducer and activator of transcription 3 (STAT3) Dominant-Negative Disease\n* STAT3 Gain-of-Function Disease\n* Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome\n* Wiskott-Aldrich Syndrome (WAS)\n* X-Linked Agammaglobulinemia (XLA)\n* X-Linked Lymphoproliferative Disease (XLP)\n* X-linked magnesium transporter 1 (MAGT1) deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect (XMEN) Disease\n* Zeta-associated protein 70 (ZAP-70) deficiency\n\nSecondary\n\n* Malnutrition\n* Uncontrolled Diabetes mellitus\n* Chronic uremia\n* Genetic syndromes: trisomy 21\n* Immunomodulatory, immunosuppressive drug therapy: corticosteroids, calcineurin inhibitors, cytotoxic agents\n* Systemic lupus erythematosus\n* Malignancy\n* Active radiation therapy\n* Bone marrow ablation\n* Infectious diseases: human immunodeficiency virus (HIV) infection, Hepatitis\n\nAdditional Primary and secondary immunodeficiencies can be found at the following link.\n\nhttps:\u002F\u002Fwww.merckmanuals.com\u002Fprofessional\u002Fimmunology-allergic-disorders\u002Fimmunodeficiency-disorders\u002Foverview-of-immunodeficiency-disorders",true,{"count":103,"type":20},72,[105],"PHASE4","Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand\u002Fforearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion\u002Fexclusion criteria. For inclusion, participants will be \\>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and\u002For systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+\u002F-2, day 14+\u002F-2, and day 30+\u002F-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand\u002Fforearm will be assessed for correlations with infections.",[108,109,110,27,111],"Cat Bite","Hand Injuries","Arm Injury","Anti-bacterial Agents","2025-10-13",{"date":114,"type":43},"2025-10-15",{"date":116,"type":43},"2023-09-07",{"date":118,"type":20},"2027-08-01",{"name":120,"class":50},"University of Missouri-Columbia",1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":21,"phases":4,"briefSummary":132,"conditions":133,"keywords":139,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100529826","towards-novel-biomarkers-to-diagnose-sepsis-on-the-emergency-room-100529826","NCT06178822","Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room","BIOSEP","Inclusion Criteria:\n\n* Age 18 years or higher\n* Presentation at the Emergency Department (ED)\n* Clinical suspicion of infection or earlier confirmed infection\n* Modified Early Warning Score (MEWS) of 2 or higher\n\nExclusion Criteria:\n\n* No informed consent given",{"count":130,"type":20},3300,"1 Year","Objectives:\n\n1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection.\n2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis.\n3. To determine the long term cognitive and physical sequelae of sepsis after admission.",[24,134,135,136,137,27,138],"Septic Shock","Sepsis, Severe","Infections","Infection Viral","Infections, Respiratory",[140,141,142,143],"Biomarkers","Emergency Room","A&E","Accident & Emergency","2025-09-29",{"date":146,"type":43},"2025-10-02",{"date":148,"type":43},"2022-10-25",{"date":150,"type":20},"2026-10-01",{"name":152,"class":50},"Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)",3,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":63,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":121},"100509542","impact-of-early-antibiotics-on-non-traumatic-out-of-hospital-cardiac-arrest-ohca-100509542","NCT05914779","Impact of Early Antibiotics on Non-Traumatic Out of Hospital Cardiac Arrest (OHCA)","Inclusion Criteria:\n\n* ● Adults aged \\>18 years, presenting to HGH ED after out-of-hospital cardiac arrest\n\n  * Patients with low likelihood of infection as per the definitions provided above\n  * Ability to obtain informed consent from the subjects or their next of kin\u002Ffamily member\u002Flegal surrogate in case of incapacitation due to sedation, mechanical ventilation, etc. In case the next of kin is not available, an independent physician who is not a part of the investigative team will complete and sign the checklist as per HMC Policy \"RES 11026\\_Appendix 6.5\". (see section 4.1.3 for details) A member of the investigative team and a witness will also sign this form before the potential subject is enrolled in the study.\n\nExclusion Criteria:\n\n* Patients who have clear evidence of infection, as defined by criteria for the study.\n\n  * Patients who have received antibiotics within the last 1 week prior to admission.\n  * Patients with malignancy, except those who have been cured or in complete remission.\n  * Females with known pregnancy.\n  * Known immunocompromised states (including HIV\u002FAIDS, transplant recipients on immunosuppressant drugs, long-term \\[\\> 3 weeks of prednisone \\>5mg\u002Fday equivalent\\] steroid therapy).\n  * Patients on immunologic disease modifying agents (commonly known as \"biologics\")\n  * Patients considered \"brain-dead\" or \"vegetative state\"\n  * Patients transferred from another hospital, long term care facility or institution\n  * Neutropenia (total WBC \\\u003C1,500\u002Fmm3 or absolute neutrophil count of \\\u003C1,000\u002Fmm3)",{"count":161,"type":20},1000,[65],"Specific Aim : The specific aim is to conduct a randomized prospective clinical trial to determine whether no antibiotics in OHCA patients in the ED with very low likelihood of infection is non-inferior to early antibiotic treatment. Hypothesis a: 28-day all-cause mortality will be non-inferior in OHCA patients with very low likelihood of infection who do not receive antibiotic therapy compared with those who receive early antibiotic therapy Hypothesis b: There will be no difference in subsequent incidence of proven infections in the no antibiotics vs, early antibiotics groups Hypothesis c: There will be no difference in the length of ICU stay and overall hospital stay in the early antibiotics vs. no antibiotics groups",[27,165],"Out-Of-Hospital Cardiac Arrest","2025-04-01",{"date":168,"type":43},"2025-04-03",{"date":170,"type":43},"2023-03-01",{"date":172,"type":20},"2025-12-31",{"name":174,"class":175},"Hamad Medical Corporation","INDUSTRY",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":63,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":121},"100528869","parenteral-versus-combined-parenteral-with-vancomycin-soaked-graft-in-acl-reconstruction-100528869","NCT06166381","Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction","Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in Decreasing the Risk of Infection in ACL Reconstruction Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* ACL injury that interferes with life activities and\u002For sports\n\nExclusion Criteria:\n\n* Patients for revision surgery of ACL reconstruction\n* patients with inflammatory rheumatological disorders\n* Refusal to participate in the study.","20 Years","45 Years",{"count":186,"type":20},288,[65],"An anterior cruciate ligament (ACL) tear is one of the knee joint's most common soft tissue injuries \\[1\\]. It is frequently injured in non-contact and some contact competition sports and even during ordinary life activities. With an annual incidence of 68.6 per 100,000 person-years, ACL tears remain a common orthopedic injury \\[2\\]. Females are two to eight times more likely to develop ACL tears in sports compared to men who play the same particular sports \\[3\\]. Most highly demanding persons and those who develop frequent instability of their knee require reconstructive surgery on the ACL to prevent early degenerative changes in their knees. This is done by completely removing the torn or ruptured ACL and replacement with a piece of tendon or ligament (graft) \\[4\\].\n\nPost-operative infection may occur in 0.14-2.6% of ACL reconstruction despite intravenous antibiotics prophylaxis \\[5,6\\]. The deep infection results in poor outcomes with pain, stiffness, arthrofibrosis, and articular cartilage degeneration \\[7,8\\]. Few studies reported improved outcomes of infection control when the autograft presoaked in vancomycin solution during the preparation process outside the body before being transferred to the knee of the patient \\[9-13\\]. Systematic reviews and meta-analysis showed that all the articles discussing the outcome of vancomycin presoaked autograft in ACL reconstruction surgery were case series, observational retrospective, prospective comparative, or case-control studies \\[14,15\\]. Randomized control trial (RCT) provides the strongest evidence among the primary research studies to confirm the effectiveness of a new method of treatment \\[16,17\\]. To date, there is no available RCT study in this field.",[27],[191,192,193,194],"Anterior cruciate ligament","reconstruction","infection","vancomycin presoaked graft","2024-12-26",{"date":197,"type":43},"2024-12-30",{"date":199,"type":43},"2024-01-25",{"date":201,"type":20},"2025-02",{"name":203,"class":50},"University of Duhok",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":121},"100451068","infectious-complications-after-cystectomy-a-prospective-observational-study-100451068","NCT05153694","Infectious Complications After Cystectomy: A Prospective Observational Study","Inclusion Criteria:\n\n* Disease which requires removal of the urinary bladder\n\nExclusion Criteria:\n\n* Patient does not want to participate",{"count":211,"type":20},200,"Patients undergoing cystectomy for either oncological or non-oncological indications are prospectively enrolled following informed consent. This study design incorporates a comprehensive medical history, detailed prospective documentation of clinicopathological parameters, and serial measurements of infectious markers pre- and post-operatively. In-hospital complications are meticulously recorded, and long-term outcomes assessed through structured follow-up interviews at 3, 6, and 12 months. These follow-ups utilize standardized questionnaires to evaluate post-discharge infectious complications and gather patients' perspectives on their in-hospital experiences, providing a robust understanding of both clinical outcomes and patient-reported experiences.",[214,136,27,215,216,217,218,219],"Bladder Cancer","Infection, Hospital","Infection Wound","Urinary Tract Infections","Urinary Bladder Diseases","Urinary Tract Disease","2024-09-13",{"date":222,"type":43},"2024-09-19",{"date":224,"type":43},"2021-12-01",{"date":172,"type":20},{"name":227,"class":50},"Ludwig-Maximilians - University of Munich",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":238,"studyType":21,"phases":4,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":121},"100396045","antibiotic-dosing-in-geriatric-patients-at-the-emergency-department-100396045","NCT04436991","Antibiotic Dosing in Geriatric Patients At the Emergency Department","AGED","Inclusion Criteria:\n\n* Patients presenting at the emergency department and later on admitted to the geriatric department\n* Patient age 75 years or older\n* Patients with geriatric profile according to KATZ scale, G8 screening test or CIRS score.\n* Patient receiving antibiotic treatment (amoxicillin-clavulanate, piperacillin-tazobactam)\n* Intravenous access available for blood sampling. For measurement of the peak concentration an intravenous access other than the drug infusion line is required.\n\nExclusion Criteria:\n\n* Admission to other units than the geriatric department incl. the ICU.\n* Absence of informed consent\n* Known hypersensitivity to beta-lactam antibiotics\n* Patients who received oral amoxicillin-clavulanate prior to admission will not be included in the iv. amoxicillin-clavulanate group.","75 Years",{"count":237,"type":20},180,"2 Weeks","In this pilot study, we will investigate whether - with the current dosing regimens, used in the Ghent University Hospital - pharmacodynamic targets regarding beta-lactam antibiotics (more specific Amoxicilline-Clavulanate, Piperacillin-Tazobactam and Temocillin) are attained in frail patients admitted to the geriatric department.",[241,242,243,27],"Elderly Infection","Frailty","Frail Elderly Syndrome",[245,246,247,248,249],"amoxicillin","piperacillin-tazobactam","temocillin","pharmacokinetics","pharmacodynamics","2024-09-05",{"date":222,"type":43},{"date":253,"type":43},"2018-01-03",{"date":255,"type":20},"2025-01",{"name":257,"class":50},"University Hospital, Ghent",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":63,"phases":268,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":279,"locationsCount":121},"100462505","phase-1-absorption-of-antibiotics-with-high-oral-bioavailability-in-short-bowel-syndrome-100462505","NCT05302531","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study","GRAAL","Inclusion Criteria:\n\n* Short bowel syndrome\n* Treated for a documented infection with antibiogram by amoxicillin (+\u002F- clavulanic acid)or ofloxacin or levofloxacin or sulfamethoxazole\u002Ftrimethoprim\n* Hospitalized in the Nutritional Assistant Unit or the Infectiology Unit of the Regional University Hospital of Nancy\n* Affiliated to a social security system\n* Having received an physical examination before entering study\n* Having received full information regarding the study organization and having signed the informed consent\n\nExclusion Criteria:\n\n* Patient at risk of worsening their oral absorption abilities during study\n* Patient requiring dialysis\n* Women of childbearing age without efficient birth control\n* Allergy to any of the drugs tested\n* Person concerned by Articles L. 1121-5, L. 1121-7 et L1121-8 of the Code of public health\n* Person deprived of liberty or person undergoing psychiatric care pursuant to articles L. 3212-1 et L. 3213-1",{"count":267,"type":20},10,[269],"PHASE1","The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.",[272,27],"Short Bowel Syndrome","2024-08-28",{"date":275,"type":43},"2024-08-29",{"date":277,"type":43},"2022-12-09",{"date":201,"type":20},{"name":280,"class":50},"Central Hospital, Nancy, France",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":289,"maxAge":17,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":51},"100517534","molecular-culture-for-the-diagnosis-of-pediatric-sepsis-100517534","NCT06018792","Molecular Culture for the Diagnosis of Pediatric Sepsis","Children's Health Assessment and Molecular Pathogen Identification for Optimized Novel Sepsis Therapy","CHAMPIONS","Inclusion Criteria:\n\n* Undergoing collection of blood for a conventional blood culture as part of standard care OR\n* Having undergone sepsis evaluation collection of blood for a conventional blood culture as part of standard care in the past 72 hours\n\nExclusion Criteria:\n\n* Apart from an age criterion, there are no strict exclusion criteria. However, for the analysis of the secondary outcome (I.e. the testing of diagnostic accuracy of both MC as well as conventional culture for clinical sepsis), we plan to exclude all children who ultimately have a clear alternative cause for clinical illness that does not directly result from bacteraemia or bacterial sepsis. This will remain true in the case of conventional culture positivity, either when considered a contaminant as well as when considered a contributing factor in the presence of any of the causes of clinical illness mentioned below. A potential subject who meets any of the following criteria will be excluded from participation in this study These causes include, but are not limited to:\n* In case of the potential inclusion of a neonate suspicious for EOS, confirmed congenital infection with TORCHES (toxoplasmosis, rubella, cytomegalovirus, syphilis and herpes) will lead to exclusion particularly for the neonatal population\n* Auto inflammatory disease\n* Hemophagocytic syndrome\n* SIRS (Systemic Inflammatory Response Syndrome following a severe viral infection","0 Years",{"count":291,"type":20},1835,"Babies and children have an increased risk of getting an infection with a bacteria in the bloodstream (sepsis). It is often difficult for the doctor to determine whether a child has an infection of the bloodstream, because the symptoms are often unclear and can also occur in children who are not sick. To determine whether there is an infection, a little blood is currently taken for a blood test (the blood culture) to investigate whether there is a bacteria in the blood. However, it often takes at least 36 hours before the results of this blood culture are available. That is why antibiotics are usually started immediately to treat the possible infection.\n\nHowever, it often turns out that the blood culture is negative after 36 hours, which means that no bacteria have been found in the blood. Usually the antibiotics are then stopped because it turns out that there was no infection at all. There is currently no good test that can predict whether (newborn) children have an infection or not. That is why too many children are currently wrongly receiving antibiotics. These antibiotics can damage the healthy bacteria in the intestines. There are many billions of 'beneficial bacteria' in the intestine. These play an important role in the digestion of food and protect against external infections. Antibiotics aim to kill bacteria that cause inflammation or infection. Unfortunately, antibiotics also kill some of these beneficial bacteria. In addition, unnecessary use of antibiotics contributes to antibiotic resistance. The aim of this research is to investigate whether Molecular Culture, a PCR based test that can identify bacterial pathogens in bodily fluids within 4 hours, has greater accuracy than traditional culturing techniques for bacteria in blood. If proven, this could lead to faster identification or exclusion of sepsis in children.",[24,294,295,27,296,297],"Sepsis Bacterial","Sepsis, Neonatal","Antibiotic Side Effect","Microbial Colonization","2024-04-09",{"date":300,"type":43},"2024-04-10",{"date":302,"type":43},"2024-03-10",{"date":304,"type":20},"2027-11-01",{"name":306,"class":50},"Jip Groen",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":316,"conditions":317,"keywords":322,"overallStatus":326,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":4},"100533019","path-study-people-with-injecting-related-infections-assessing-treatment-outcomes-for-those-who-are-hospitalised-100533019","NCT06220370","PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.","PATH","Inclusion Criteria:\n\n1. Have voluntarily signed the informed consent form,\n2. 18 years of age or older,\n3. Injected drugs within the last 6 months,\n4. Admitted to hospital with invasive bacterial or fungal infection, a. Examples of invasive infection include: bloodstream infection, bone and joint infection (osteomyelitis, septic arthritis, discitis), central nervous system infection (epidural abscess, meningitis), deep abscess (i.e., brain, liver, muscle, spleen), endovascular infection (infective endocarditis, septic thrombophlebitis, mycotic aneurysm, septic embolism), skin or soft tissue infection (necrotising fasciitis, myositis),\n\nExclusion Criteria:\n\n1\\) Is unable or unwilling to provide informed consent or abide by the requirements of the study.",{"count":315,"type":20},300,"We seek to characterise the burden and outcomes of and understand the current experience of people who inject drugs admitted to hospital with invasive injecting-related infections, in order to implement and evaluate strategies to improve completion of therapy and reduce patient-directed discharges, with ultimate benefit to the patient and health service.",[318,319,320,27,28,321],"Invasive Fungal Infections","Invasive Bacterial Infection","Injection Site Infection","Infection, Soft Tissue",[323,324,325],"Antimicrobial therapy","Patient-directed discharge","Injection-related infectious diseases","NOT_YET_RECRUITING","2024-02-18",{"date":329,"type":43},"2024-02-20",{"date":331,"type":20},"2024-03-01",{"date":333,"type":20},"2029-03-01",{"name":335,"class":336},"Kirby Institute","OTHER_GOV"]